Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Merck and Eisai halt late-stage trial as Keytruda/Lenvima combo fails to improve survival in liver cancer. Read more here.

The Capitals’ captain has two goals in 12 games. The streaky scorer is confident that goals will come. The banners that track ...

Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer lived without their disease progressing, in a late-stage study, the ...

The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...

Soon after returning to the White House, Mr. Trump issued a sweeping order to halt all leasing of federal lands and waters ...

A recent study from Oregon State University estimated that more than 3,500 animal species are at risk of extinction because ...

West Ham face crucial test as Paqueta’s future uncertainty growsPressure mounts amid Paqueta speculationWest Ham United are ...

What makes athletes mentally tough? Research points to two coaching approaches that work side by side to build psychological ...

Two weeks into the new school year, Principal Sherree Lewis-DeVaughn eagerly showed off improvements to 135th Elementary ...

HCV incidence among people who inject drugs in Scotland has halved since 2015, bringing WHO elimination targets within reach.